Boehringer Ingelheim

This study tests whether adding a new drug called vicadrostat to the existing medication empagliflozin can lower the risk of heart problems in adults with type 2 diabetes, high blood pressure, and heart disease. About 11,800 participants will be randomly assigned to receive eithe…

This study tests a new drug, BI 1703880, combined with ezabenlimab for adults with advanced solid tumors who have no other treatment options. The main goal is to find a safe dose. Both drugs are given through a vein and aim to help the immune system fight cancer. Participants rec…

This study tests a new drug, BI 3820768, in adults with advanced germ cell, endometrial, or ovarian cancer that has not responded to prior treatments. The drug aims to help the immune system fight cancer. Participants receive weekly injections for two 3-week cycles, then every 3 …

This study tests if empagliflozin, a drug used for diabetes, can help children aged 2 to 17 with chronic kidney disease. About 120 kids will take either the drug or a placebo for 6 months, then everyone gets the drug for a year. Researchers will check kidney function and safety t…

This study tests whether adding vicadrostat to the standard drug empagliflozin helps people with heart failure who have a preserved ejection fraction (heart pumps normally but still causes symptoms). About 6000 adults with heart failure symptoms will be randomly assigned to recei…

This study tests a once-daily tablet called BI 1291583 in adults and teens (ages 12 and up) with bronchiectasis who produce sputum and have had flare-ups. About 1755 participants will be randomly assigned to receive the drug or a placebo for up to 76 weeks. The main goal is to se…

This study tests a new medicine called BI 765423 for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and makes breathing hard. About 71 adults aged 40 and older will receive either the study drug or a placebo by IV every four weeks for 3 month…

This study tests an experimental oral medicine, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of BI 3000202 or a placebo, taken daily for a year, while continuing their usual lupus tre…

This study tests if spesolimab can close painful skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory condition. About 90 participants will receive either the drug or a placebo, along with oral steroids for the first 8 weeks. The main goal is complete ulcer closur…

This early-phase study tests a new drug, BI 3810944, in 69 adults with advanced solid tumors or melanoma who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously, usually every three w…

This early-phase study tests a new drug, BI 1831169, in adults with advanced solid tumors that cannot be removed by surgery. The drug is given alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it can shrink tumors. About 190 participants wil…

This study tests whether combining three different medicines can shrink tumors in people with head and neck cancer that has spread or come back. About 90 adults will receive either a two-drug or three-drug combination, or a single drug alone. The goal is to see if the combination…

This study tests a new drug called obrixtamig in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker (DLL3). The goal is to find the safest dose and schedule. Participants receive the drug weekly or every 3 weeks for up to 3 yea…

This study looks at how a medicine called BI 1291583, being developed for a chronic lung disease called bronchiectasis, behaves in people with different levels of liver function. About 32 adults, some with mild to severe liver problems and some with healthy livers, will take a si…

This study tests whether a single dose of vicadrostat affects the heart's electrical activity in 45 healthy adults aged 18 to 50. Participants receive vicadrostat, placebo, or moxifloxacin in random order. The goal is to see if vicadrostat causes any heart rhythm changes, helping…

This early-stage study is testing a new drug called BI 3031185 in 60 healthy men aged 18 to 50. The goal is to see if the drug is safe and how the body processes it when taken by mouth multiple times. Participants will be randomly assigned to receive either the drug or a placebo,…

This study looks at how a medicine called BI 3000202 is handled by the body in people with and without liver problems. About 44 adults aged 18 to 80 will take a single tablet and have their blood tested over a month. The goal is to understand if liver impairment changes drug leve…

This early-stage study is testing a new drug called BI 3776528 in 142 healthy men aged 18 to 50. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo. This study does not aim to treat any disease.

This study looks at how two weight-loss drugs, BI 456906 and semaglutide, attach to receptors in the liver and pancreas. About 30 adults with obesity will get either drug for 17 weeks. Before and after treatment, doctors use PET and MRI scans to see how much the drugs occupy thes…

This study looks at how pirfenidone, a common IPF medicine, changes the amount of a new drug called BI 1015550 in the blood. About 20 adults with IPF, aged 40 and older, will take one dose of BI 1015550, then pirfenidone for three weeks, and then another dose of BI 1015550. Resea…